On June 7, the House passed, 367-58, the FY2001 defense appropriations bill (H.R. 4576). Upon receiving the House bill, the Senate began consideration of its version of the bill (S. 2593) on June 8. A vote on final passage of the Senate bill is expected by June 13.
Both bills would level-fund peer-reviewed breast cancer research at the Department of Defense (DoD) at $175 million. Ovarian cancer research would be level-funded at $12 million under the Senate bill, while the House bill would provide $10 million for the program. While osteoporosis research would receive $7.5 million under the Senate bill, the program did not receive a line-item under the House bill. Last year, Congress appropriated $4 million for osteoporosis research, but DoD added an additional $2.5 million, as requested by the President, bringing total funding for FY2000 to $6.5 million.
Additionally, the House bill would provide $3 million for cervical cancer vaccine research. Such research has not previously received a line-item in the DoD spending bill.